

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) the sequences provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;

(b) the complements of the sequences provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;

(c) ~~sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;~~

(d) ~~sequences that hybridize to a sequence provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431, under highly stringent conditions;~~

(e) ~~sequences having at least 75% identity to a sequence of SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431;~~

(f) ~~sequences having at least 90% identity to a sequence of SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431; and~~

(g) degenerate variants of a the sequence provided in SEQ ID NOs:128, 129, 132, 160, 167, 168, 254, 358, 370-375, and 431, wherein the degenerate variants encode the polypeptide provided in SEQ ID NO:161.

2. (Canceled)

3. (Original) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Currently Amended) An isolated host cell transformed or transfected with an expression vector according to claim 3.

5.-10 (Canceled)

11. (Previously Presented) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising the isolated polynucleotide according to claim 1.

12. (Currently Amended) A method for stimulating an immune response in a patient, comprising administering to the patient a suitable dose of the composition of claim 11, thereby stimulating an immune response in the patient.

13.-17. (Canceled)